Blood, a peer-reviewed publication has published data from a Phase 1/2 study of voxelotor, which belongs to Global Blood Therapeutics, Inc. The treatment is primarily for patients with sickle cell disease (SCD), and the target is to develop it as a potential disease-modifying therapy for SCD. Global Blood Therapeutics Inc. (NASDAQ:GBT) up 0.74% in the previous trading session and is trending upwards. This is the possible reason why the stock continues to gain.

SCD is an extended life condition, and it causes sickle hemoglobin (HbS). Its patients suffer from unpredictable and recurrent episodes of severe pain resulting from blocked blood flow to organs. More often than not and if not attended early enough, it can lead to physical disabilities.

GBT believes that voxelotor may potentially modify the course of SCD

“Despite the complex nature of the disease, SCD patients have had limited treatment options for decades, and it is critical that we continue to advance the development of new medicines.” This is according to the president of the American Society of Hematology, Alexis Thompson. In this spirit, GTB says it will be submitting a New Drug Application (NDA) for voxelotor, and it anticipates that it will get an approval from the FDA later this year.

The findings from the Phase 1/2 study have triggered the anticipation for the approval. Besides, the FDA is willing to walk with GTB in its endeavor to pursue new innovative therapies for SCD. The agency has also acknowledged the urgent need for addressing the SCD community. GTB’s CEO Ted W. Love says that FDA’s continuous commitment to fighting the devastating disease is encouraging.

GBT is currently evaluating voxelotor in the HOPE study

HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) a Phase 3 clinical study is targeting SCD patients of age 12 and older. This is in addition to an ongoing Phase 2a HOPE-KIDS 1 Study, which is examining the safety and tolerability of voxelotor.

Meanwhile, GTB has offered three new employees an opportunity to buy an aggregate of 6,000 of the Company’s common stock shares. This is an inducement material, which adopted in 2017 and it is mainly for the employees joining the company.

Looking for the next Pfizer (PFE) or Johnson&Johnson (JNJ)? Take advantage of Kyle Dennis’ free biotech trader’s handbook and how he made his first $2.9 Million in the market. The smart money is pouring into this sector and you’ll want to grab a piece of this action! Which company is next to explode?